Cardiovascular consequences of alcohol and other drug use

The ASAM Principles of Addiction Medicine: Fifth Edition

Volumn , Issue , 2014, Pages

  Pfau, Steven ^a   Friedman, Howard S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979910690     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (258)

1. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999; 353(9147): 89-92.
2. George A, Figueredo VM. Alcoholic cardiomyopathy: a review. J Card Fail 2011; 17(10): 844-849.
3. Malinski Mk, Sesso HD, Lopez-Jimenez F, et al. Alcohol consumption and cardiovascular disease mortality in hypertensive men. Arch Intern Med 2004; 164(6): 623-628.
4. Costanzo S, Di Castelnuovo A, Donati MB, et al. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2010; 55(13): 1339-1347.
5. Reid M, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 1999; 159(15): 1681-1689.
6. Kelbaek H, Gjorup T, Hartling OJ, et al. Left ventricular function during alcohol intoxication and autonomic nervous blockade. Am J Cardiol 1987; 59(6): 685-688.
7. Altura BM, Altura BT. Microvascular and vascular smooth muscle actions of ethanol, acetaldehyde, and acetate. Fed Proc 1982; 41(8): 2447-2451.
8. Riff DP, Jain AC, Doyle JT. Acute hemodynamic effects of ethanol on normal human volunteers. Am Heart J 1969; 78(5): 592-597.
9. Blomqvist G, Saltin B, Mitchell JH. Acute effects of ethanol ingestion on the response to submaximal and maximal exercise in man. Circulation 1970; 42(3): 463-470.
10. Delgado CE, Gortuin NJ, Ross RS. Acute effects of low doses of alcohol on left ventricular function by echocardiography. Circulation 1975; 51(3): 535-540.
11. Patel VB, Why HJ, Richardson PJ, et al. The effects of alcohol on the heart. Adverse Drug React Toxicol Rev 1997; 16(1): 15-43.
12. Williams ES, Mirro MJ, Bailey JC. Electrophysiological effects of ethanol, acetaldehyde, and acetate on cardiac tissues from dog and guinea pig. Circ Res 1980; 47(3): 473-478.
13. Thomas AP, Sass EJ, Tun-Kirchmann TT, et al. Ethanol inhibits electrically-induced calcium transients in isolated rat cardiac myocytes. J Mol Cell Cardiol 1989; 21(6): 555-565.
14. Danziger RS, Sakai M, Capogrossi MC, et al. Ethanol acutely and reversibly suppresses excitation-contraction coupling in cardiac myocytes. Circ Res 1991; 68(6): 1660-1668.
15. Mongo KG, Vassort G. Inhibition by alcohols, halothane and chloroform of the Ca current in single frog ventricular cells. J Mol Cell Cardiol 1990; 22(9): 939-953.
16. Guarnieri T, Lakatta EG. Mechanism of myocardial contractile depression by clinical concentrations of ethanol. A study in ferret papillary muscles. J Clin Invest 1990; 85(5): 1462-1467.
17. Lange LG, Sobel BE. Myocardial metabolites of ethanol. Circ Res 1983; 52(4): 479-482.
18. Preedy VR, Atkinson LM, Richardson PJ, et al. Mechanisms of ethanol-induced cardiac damage. Br Heart J 1993; 69(3): 197-200.
19. Fernandez-Sola J, Nicolas JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002;137(5 Part 1): 321-326.
20. Okuno F, Arai M, Ishii H, et al. Mild but prolonged elevation of serum angiotensin converting enzyme (ACE) activity in alcoholics. Alcohol 1986; 3(6): 357-359.
21. Cheng CP, Cheng HJ, Cunningham C, et al. Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation 2006; 114(3): 226-236.
22. Ripoll C, Yotti R, Bermejo J, et al. The heart in liver transplantation. J Hepatol 2011; 54(4): 810-822.
23. Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 2002; 121(5): 1638-1650.
24. Regan TJ. Alcoholic cardiomyopathy. Prog Cardiovasc Dis 1984; 27(3): 141-152.
25. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64(7): 830-842.
26. Kajander OA, Kupari M, Laippala P, et al. Dose dependent but non-linear effects of alcohol on the left and right ventricle. Heart 2001; 86(4): 417-423.
27. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274(2): 149-154.
28. Fernandez-Sola J, Estruch R, Nicolas JM, et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80(4): 481-485.
29. Estruch R, Fernandez-Sola J, Sacanella E, et al. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995; 22(2): 532-538.
30. Henriksen JH, Moller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J 2009; 43(4):218-225.
31. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53(1): 179-190.
32. Mathews EC, Jr, Gardin JM, Henry WL, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47(3): 570-578.
33. Lazarevic AM, Nakatani S, Neskovic AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35(6): 1599-1606.
34. Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54(7): 852-855.
35. Davidson DM. Cardiovascular effects of alcohol. West J Med 1989; 151(4): 430-439.
36. McKenna CJ, Codd MB, McCann HA, et al. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998;135(5 Pt 1):833-837.
37. Ho KK, Anderson KM, Kannel WB, et al. Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects. Circulation 1993; 88(1): 107-115.
38. Corrao G, Rubbiati L, Bagnardi V, et al. Alcohol and coronary heart disease: a meta-analysis. Addiction 2000; 95(10): 1505-1523.
39. Britton KA, Gaziano JM, Sesso HD, et al. Relation of alcohol consumption and coronary heart disease in hypertensive male physicians (from the Physicians' Health Study). Am J Cardiol 2009; 104(7): 932-935.
40. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119(14): e391-e479.
41. Dickerson JA, Raman SV, Baker PM, et al. Relationship of cardiac magnetic resonance imaging and myocardial biopsy in the evaluation of nonischemic cardiomyopathy. Congest Heart Fail 2013; 19(1): 29-38.
42. Bluemke DA. MRI of nonischemic cardiomyopathy. AJR Am J Roentgenol 2010; 195(4): 935-940.
43. Shehata ML, Turkbey EB, Vogel-Claussen J, et al. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies. Top Magn Reson Imaging 2008; 19(1): 43-57.
44. La Vecchia LL, Bedogni F, Bozzola L, et al. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol 1996; 19(1): 45-50.
45. Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997; 79(9): 1276-1278.
46. Nicolas JM, Fernandez-Sola J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002; 136(3): 192-200.
47. Fauchier L, Babuty D, Poret P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000; 21(4): 306-314.
48. Hookana E, Junttila MJ, Puurunen VP, et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm 2011; 8(10): 1570-1575.
49. Laonigro I, Correale M, Di Biase M, et al. Alcohol abuse and heart failure. Eur J Heart Fail 2009; 11(5): 453-462.
50. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154-e235.
51. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125(15): 1928-1952.
52. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14(2): 159-172.
53. Rehm J, Room R, Monteiro M, et al. Alcohol as a risk factor for global burden of disease. Eur Addict Res 2003; 9(4): 157-164.
54. Beilin LJ, Puddey IB. Alcohol and hypertension: an update. Hypertension 2006; 47(6): 1035-1038.
55. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52(22): 1749-1757.
56. Grassi GM, Sommers VK, Rek WS, et al. Effects of alcohol intake on blood pressure and sympathetic nerve activity in normotensive humans: a preliminary report. J Hypertens Suppl 1989; 7(Suppl 6): S20-S21.
57. Randin D, Vollenweider P, Tappy L, et al. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 1995; 332(26): 1733-1737.
58. van de Borne P, Mark AL, Montano N, et al. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension 1997; 29(6): 1278-1283.
59. Abdel-Rahman AR, Merrill RH, Wooles WR. Effect of acute ethanol administration on the baroreceptor reflex control of heart rate in normotensive human volunteers. Clin Sci (Lond) 1987; 72(1): 113-122.
60. Klatsky AL, Friedman GD, Siegelaub AB, et al. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med 1977; 296(21): 1194-1200.
61. Zilkens RR, Burke V, Hodgson JM, et al. Red wine and beer elevate blood pressure in normotensive men. Hypertension 2005; 45(5): 874-879.
62. Hering D, Kucharska W, Kara T, et al. Potentiated sympathetic and hemodynamic responses to alcohol in hypertensive vs. normotensive individuals. J Hypertens 2011; 29(3): 537-541.
63. McAdam-Marx C, Ye X, Sung JC, et al. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009; 31(5): 1116-1123.
64. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57(6): 1076-1080.
65. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18(11): 1422-1428.
66. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125(13): 1635-1642.
67. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001; 38(5): 1112-1117.
68. McFadden CB, Brensinger CM, Berlin JA, et al. Systematic review of the effect of daily alcohol intake on blood pressure. Am J Hypertens 2005;18(2 Pt 1):276-286.
69. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-1252.
70. Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 2011; 124(18): 1982-1993.
71. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8): 949-953.
72. Schoonderwoerd BA, Smit MD, Pen L, et al. New risk factors for atrial fibrillation: causes of "not-so-lone atrial fibrillation." Europace 2008; 10(6): 668-673.
73. Djousse L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93(6): 710-713.
74. Mukamal KJ, Psaty BM, Rautaharju PM, et al. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. Am Heart J 2007; 153(2): 260-266.
75. Kodama S, Saito K, Tanaka S, et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2011; 57(4): 427-436.
76. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004; 164(18): 1993-1998.
77. Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005; 112(12): 1736-1742.
78. Kelbaek H, Gjorup T, Brynjolf I, et al. Acute effects of alcohol on left ventricular function in healthy subjects at rest and during upright exercise. Am J Cardiol 1985; 55(1): 164-167.
79. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114(7): e257-e354.
80. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136(3): 181-191.
81. Klatsky AL. Alcohol and cardiovascular mortality: common sense and scientific truth. J Am Coll Cardiol 2010; 55(13): 1336-1338.
82. Mukamal KJ, Chen CM, Rao SR, et al. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol 2010; 55(13): 1328-1335.
83. Zhou X, Li C, Xu W, et al. Relation of alcohol consumption to angiographically proved coronary artery disease in chinese men. Am J Cardiol 2010; 106(8): 1101-1103.
84. Roy A, Prabhakaran D, Jeemon P, et al. Impact of alcohol on coronary heart disease in Indian men. Atherosclerosis 2010; 210(2): 531-535.
85. Zakhari S. Molecular mechanisms underlying alcohol-induced cardioprotection: contribution of hemostatic components. Introduction to the symposium. Alcohol Clin Exp Res 1999; 23(6): 1108-1110.
86. Booyse FM, Parks DA. Moderate wine and alcohol consumption: beneficial effects on cardiovascular disease. Thromb Haemost 2001; 86(2): 517-528.
87. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329(25): 1829-1834.
88. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002; 287(19): 2559-2562.
89. Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 2009; 32(11): 2123-2132.
90. Di Minno MN, Franchini M, Russolillo A, et al. Alcohol dosing and the heart: updating clinical evidence. Semin Thromb Hemost 2011; 37(8): 875-884.
91. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002; 105(24): 2836-2844.
92. White IR, Altmann DR, Nanchahal K. Alcohol consumption and mortality: modelling risks for men and women at different ages. BMJ 2002; 325(7357): 191.
93. Di Castelnuovo A, Costanzo S, Bagnardi V, et al. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 2006;166(22):2437-2445. http://archinte.jamanetwork.com/article.aspx?articleid=769554
94. Yang T, Doherty TM, Wong ND, et al. Alcohol consumption, coronary calcium, and coronary heart disease events. Am J Cardiol 1999; 84(7): 802-806.
95. Pletcher MJ, Varosy P, Kiefe CI, et al. Alcohol consumption, binge drinking, and early coronary calcification: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 2005; 161(5): 423-433.
96. McClelland RL, Bild DE, Burke GL, et al. Alcohol and coronary artery calcium prevalence, incidence, and progression: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2008; 88(6): 1593-1601.
97. Vliegenthart R, Oei HH, van den Elzen AP, et al. Alcohol consumption and coronary calcification in a general population. Arch Intern Med 2004; 164(21): 2355-2360.
98. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.
99. Reynolds K, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289(5): 579-588.
100. Vital signs: current cigarette smoking among adults aged ≥18 years-United States, 2005-2010. MMWR Morb Mortal Wkly Rep 2011;60(35):1207-1212.
101. Cryer PE, Haymond MW, Santiago JV, et al. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295(11): 573-577.
102. Benowitz NL, Jacob P III, Jones RT, et al. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221(2): 368-372.
103. Grassi G, Seravalle G, Calhoun DA, et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994; 90(1): 248-253.
104. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29(7): 1422-1431.
105. Niedermaier ON, Smith ML, Beightol LA, et al. Influence of cigarette smoking on human autonomic function. Circulation 1993; 88(2): 562-571.
106. Adamopoulos D, van de Borne P, Argacha JF. New insights into the sympathetic, endothelial and coronary effects of nicotine. Clin Exp Pharmacol Physiol 2008; 35(4): 458-463.
107. Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J 1985; 54(2): 222-223.
108. Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986; 255(8): 1018.
109. Mehta MC, Jain AC, Mehta A, et al. Cardiac arrhythmias following intravenous nicotine: experimental study in dogs. J Cardiovasc Pharmacol Ther 1997; 2(4): 291-298.
110. Miyauchi M, Qu Z, Miyauchi Y, et al. Chronic nicotine in hearts with healed ventricular myocardial infarction promotes atrial flutter that resembles typical human atrial flutter. Am J Physiol Heart Circ Physiol 2005; 288(6): H2878-H2886.
111. Wang H, Shi H, Wang Z. Nicotine depresses the functions of multiple cardiac potassium channels. Life Sci 1999; 65(12): PL143-PL149.
112. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335(24): 1792-1798.
113. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012; 110(7): 968-970.
114. D'Alessandro A, Boeckelmann I, Hammwhoner M, et al. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol 2012; 19(3): 297-305.
115. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
116. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362(6423): 801-809.
117. Ruberg FL, Loscalzo J. Prothrombotic determinants of coronary atherothrombosis. Vasc Med 2002; 7(4): 289-299.
118. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8(9): 502-512.
119. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43(10): 1731-1737.
120. Blann AD, Steele C, McCollum CN. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb Haemost 1997; 78(3): 1093-1096.
121. Talhout R, Schulz T, Florek E, et al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011; 8(2): 613-628.
122. Kugiyama K, Yasue H, Ohgushi M, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol 1996; 28(5): 1161-1167.
123. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104(16): 1905-1910.
124. Blann AD, Kirkpatrick U, Devine C, et al. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 1998; 141(1): 133-139.
125. Bermudez EA, Rifai N, Buring JE, et al. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002; 89(9): 1117-1119.
126. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997; 29(3): 491-497.
127. Rival J, Riddle JM, Stein PD. Effects of chronic smoking on platelet function. Thromb Res 1987; 45(1): 75-85.
128. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113(4): 1006-1010.
129. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294(14): 1799-1809.
130. Ramsdale DR, Faragher EB, Bray CL, et al. Smoking and coronary artery disease assessed by routine coronary arteriography. Br Med J (Clin Res Ed) 1985; 290(6463): 197-200.
131. Waters D, Lesperance J, Gladstone P, et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation 1996; 94(4): 614-621.
132. Howard G, Burke GL, Szklo M, et al. Active and passive smoking are associated with increased carotid wall thickness. The Atherosclerosis Risk in Communities Study. Arch Intern Med 1994; 154(11): 1277-1282.
133. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012; 308(16): 1660-1667.
134. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365(9470): 1577-1589.
135. Inoue T, Oku K, Kimoto K, et al. Relationship of cigarette smoking to the severity of coronary and thoracic aortic atherosclerosis. Cardiology 1995; 86(5): 374-379.
136. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259(7): 1025-1029.
137. Rogot E, Murray JL. Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep 1980; 95(3): 213-222.
138. Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316(7137): 1043-1047.
139. Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1(7904): 415-420.
140. Gordon T, Kannel WB, McGee D, et al. Death and coronary attacks in men after giving up cigarette smoking. A report from the Framingham study. Lancet 1974; 2(7893): 1345-1348.
141. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976; 2(6051): 1525-1536.
142. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 2008; 359(5): 482-491.
143. Juster HR, Loomis BR, Hinman TM, et al. Declines in hospital admissions for acute myocardial infarction in New York state after implementation of a comprehensive smoking ban. Am J Public Health 2007; 97(11): 2035-2039.
144. Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation 2006; 114(14): 1490-1496.
145. Bruintjes G, Bartelson BB, Hurst P, et al. Reduction in acute myocardial infarction hospitalization after implementation of a smoking ordinance. Am J Med 2011; 124(7): 647-654.
146. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322(4): 213-217.
147. Kloner RA, Hale S, Alker K, et al. The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85(2): 407-419.
148. Pitts WR, Lange RA, Cigarroa JE, et al. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40(1): 65-76.
149. Shannon RP, Mathier MA, Shen Y. Role of cardiac nerves in the cardiovascular response to cocaine in conscious dogs. Circulation 2001; 103(12): 1674-1680.
150. Trendelenburg U. The effect of cocaine on the pacemaker of isolated guinea-pig atria. J Pharmacol Exp Ther 1968; 161(2): 222-231.
151. Greenberg R, Innes IR. The role of bound calcium in supersensitivity induced by cocaine. Br J Pharmacol 1976; 57(3): 329-334.
152. Richie JM, Rall TW, Nies AS, et al. The pharmacologic basis of therapeutics, 7th ed. New York, NY: Pergamon Press, 1990.
153. Josephson I, Sperelakis N. Local anesthetic blockade of Ca2+- mediated action potentials in cardiac muscle. Eur J Pharmacol 1976; 40(2): 201-208.
154. Kimura S, Bassett AL, Xi H, Myerburg RJ. Early afterdepolarizations and triggered activity induced by cocaine. A possible mechanism of cocaine arrhythmogenesis. Circulation 1992; 85(6): 2227-2235.
155. Egashira K, Morgan KG, Morgan JP. Effects of cocaine on excitation-contraction coupling of aortic smooth muscle from the ferret. J Clin Invest 1991; 87(4): 1322-1328.
156. Finkel JB, Marhefka GD. Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc 2011; 86(12): 1198-1207.
157. The DAWN Report: Emergency Department Visits Involving Illicit Drug Use by Older Adults: 2008. [Online Website]. September 9, 2010:http://oas.samhsa.gov/2k10/DAWN015/IllicitAbuseHTML.pdf
158. Basso C, Marra MP, Thiene G. Cocaine and the heart: more than just coronary disease. Heart 2011; 97(24): 1995-1996.
159. Paraschin K, Guerra De Andrade A, et al. Assessment of myocardial infarction by CT angiography and cardiovascular MRI in patients with cocaine-associated chest pain: a pilot study. Br J Radiol 2012; 85(1015): e274-278.
160. Aquaro GD, Gabutti A, Meini M, et al. Silent myocardial damage in cocaine addicts. Heart 2011; 97(24): 2056-2062.
161. Resnick RB, Kestenbaum RS, Schwartz LK. Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 1977; 195(4279): 696-698.
162. Fischman MW, Schuster CR, Javaid J, et al. Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 1985; 235(3): 677-682.
163. Whitby LG, Hertting G, Axelrod J. Effect of cocaine on the disposition of noradrenaline labelled with tritium. Nature 1960; 187: 604-605.
164. Brogan WC III, Lange RA, Kim AS, et al. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol 1991; 18(2): 581-586.
165. Boehrer JD, Moliterno DJ, Willard JE, et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993; 94(6): 608-610.
166. Flores ED, Lange RA, Cigarroa RG, et al. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses. J Am Coll Cardiol 1990; 16(1): 74-79.
167. Moliterno DJ, Willard JE, Lange RA, et al. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med 1994; 330(7): 454-459.
168. Pereira J, Saez CG, Pallavicini J, et al. Platelet activation in chronic cocaine users: effect of short term abstinence. Platelets 2011; 22(8): 596-601.
169. Heesch CM, Wilhelm CR, Ristich J, et al. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart 2000; 83(6): 688-695.
170. Rinder HM, Ault KA, Jatlow PI, et al. Platelet alpha-granule release in cocaine users. Circulation 1994; 90(3): 1162-1167.
171. Pradhan L, Mondal D, Chandra S, et al. Molecular analysis of cocaine-induced endothelial dysfunction: role of endothelin-1 and nitric oxide. Cardiovasc Toxicol 2008; 8(4): 161-171.
172. Siegel AJ, Mendelson JH, Sholar MB, et al. Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. Am J Cardiol 2002; 89(9): 1133-1135.
173. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102(14): 1634-1638.
174. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31(7): 1460-1465.
175. Kolodgie FD, Virmani R, Cornhill JF, et al. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol 1991; 17(7): 1553-1560.
176. Wilson LD, Malik M, Willson H. Cocaine and ethanol: combined effects on coronary artery blood flow and myocardial function in dogs. Acad Emerg Med 2009; 16(7): 646-655.
177. Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99(21): 2737-2741.
178. Feldman JA, Fish SS, Beshansky JR, et al. Acute cardiac ischemia in patients with cocaine-associated complaints: results of a multicenter trial. Ann Emerg Med 2000; 36(5): 469-476.
179. Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med 1994; 1(4): 330-339.
180. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57(19): 1920-1959.
181. Chase M, Brown AM, Robey JL, et al. Application of the TIMI risk score in ED patients with cocaine-associated chest pain. Am J Emerg Med 2007; 25(9): 1015-1018.
182. Dribben WH, Kirk MA, Trippi JA, et al. A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain. Ann Emerg Med 2001; 38(1): 42-48.
183. Kontos MC, Anderson FP, Ornato JP, et al. Utility of troponin I in patients with cocaine-associated chest pain. Acad Emerg Med 2002; 9(10): 1007-1013.
184. Gitter MJ, Goldsmith SR, Dunbar DN, et al. Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med 1991; 115(4): 277-282.
185. Weber JE, Shofer FS, Larkin GL, et al. Validation of a brief observation period for patients with cocaine-associated chest pain. N Engl J Med 2003; 348(6): 510-517.
186. Baumann BM, Perrone J, Hornig SE, et al. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med 2000; 7(8): 878-885.
187. Honderick T, Williams D, Seaberg D, et al. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med 2003; 21(1): 39-42.
188. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126(7): 875-910.
189. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50(7): e1-e157.
190. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112(12): 897-903.
191. Dattilo PB, Hailpern SM, Fearon K, et al. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med 2008; 51(2): 117-125.
192. Rangel C, Shu RG, Lazar LD, et al. Beta-blockers for chest pain associated with recent cocaine use. Arch Intern Med 2010; 170(10): 874-879.
193. Hoskins MH, Leleiko RM, Ramos JJ, et al. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. J Cardiovasc Pharmacol Ther 2010; 15(1): 47-52.
194. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305(16): 1677-1684.
195. Grines CL, Topol EJ, O'Neill WW, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995; 91(2): 298-303.
196. Hollander JE, Burstein JL, Hoffman RS, et al. Cocaine-associated myocardial infarction. Clinical safety of thrombolytic therapy. Cocaine Associated Myocardial Infarction (CAMI) Study Group. Chest 1995; 107(5): 1237-1241.
197. Newell MC, Henry JT, Henry TD, et al. Impact of age on treatment and outcomes in ST-elevation myocardial infarction. Am Heart J 2011; 161(4): 664-672.
198. Karlsson G, Rehman J, Kalaria V, et al. Increased incidence of stent thrombosis in patients with cocaine use. Catheter Cardiovasc Interv 2007; 69(7): 955-958.
199. Daniel JC, Huynh TT, Zhou W, et al. Acute aortic dissection associated with use of cocaine. J Vasc Surg 2007; 46(3): 427-433.
200. Prakash SK, Haden-Pinneri K, Milewicz DM. Susceptibility to acute thoracic aortic dissections in patients dying outside the hospital: an autopsy study. Am Heart J 2011; 162(3): 474-479.
201. Hsue PY, Salinas CL, Bolger AF, et al. Acute aortic dissection related to crack cocaine. Circulation 2002; 105(13): 1592-1595.
202. Eagle KA, Isselbacher EM, DeSanctis RW. Cocaine-related aortic dissection in perspective. Circulation 2002; 105(13): 1529-1530.
203. Roll JM, Higgins ST, Tidey J. Cocaine use can increase cigarette smoking: evidence from laboratory and naturalistic settings. Exp Clin Psychopharmacol 1997; 5(3): 263-268.
204. Wallace EA, Wisniewski G, Zubal G, et al. Acute cocaine effects on absolute cerebral blood flow. Psychopharmacology (Berl) 1996; 128(1): 17-20.
205. Kolodgie FD, Farb A, Virmani R. Pathobiological determinants of cocaine-associated cardiovascular syndromes. Hum Pathol 1995; 26(6): 583-586.
206. Pons-Llado G, Carreras F, Borras X, et al. Findings on Doppler echocardiography in asymptomatic intravenous heroin users. Am J Cardiol 1992; 69(3): 238-241.
207. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372(9651): 1733-1745.
208. Cooper HL, Brady JE, Ciccarone D, et al. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis 2007; 45(9): 1200-1203.
209. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis 2000; 30(2): 374-379.
210. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine 1983; 62(3): 170-177.
211. DeWitt DE, Paauw DS. Endocarditis in injection drug users. Am Fam Physician 1996; 53(6): 2045-2049.
212. Sousa C, Botelho C, Rodrigues D, et al. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis 2012; 31(11): 2905-2910.
213. Baddley JW, Benjamin DK, Jr., Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27(7): 519-529.
214. Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 2012; 18(4): E99-E109.
215. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach and therapeutic options. Prog Cardiovasc Dis 2008; 50(4): 274-281.
216. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104(7): 1085-1099.
217. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12(2): 245-258.
218. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290(1): 136-145.
219. Gray SD, Fatovich DM, McCoubrie DL, et al. Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 2007; 186(7): 336-339.
220. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999; 44(2): 359-368.
221. Kaye S, McKetin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102(8): 1204-1211.
222. Turnipseed SD, Richards JR, Kirk JD, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med 2003; 24(4): 369-373.
223. Ali WM, Al Habib KF, Al-Motarreb A, et al. Acute coronary syndrome and khat herbal amphetamine use: an observational report. Circulation 2011; 124(24): 2681-2689.
224. Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64(4): 495-502.
225. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343(25): 1826-1832.
226. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63(6): 1223-1229.
227. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356(1): 6-9.
228. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9): 581-588.
229. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med 2007; 120(2): 165-171.
230. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265(9): 1152-1154.
231. Wijetunga M, Seto T, Lindsay J, et al. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol 2003; 41(7): 981-986.
232. Smith HJ, Roche AH, Jausch MF, et al. Cardiomyopathy associated with amphetamine administration. Am Heart J 1976; 91(6): 792-797.
233. Diercks DB, Fonarow GC, Kirk JD, et al. Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 2008; 102(9): 1216-1219.
234. Karch SB. The unique histology of methamphetamine cardiomyopathy: a case report. Forensic Sci Intern 2011; 212(1-3): e1-e4.
235. He SY, Matoba R, Fujitani N, et al. Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol 1996; 17(2): 155-162.
236. Maeno Y, Iwasa M, Inoue H, et al. Direct effects of methamphetamine on hypertrophy and microtubules in cultured adult rat ventricular myocytes. Forensic Sci Intern 2000; 113(1-3): 239-243.
237. Nef HM, Mollmann H, Akashi YJ, et al. Mechanisms of stress (Takotsubo) cardiomyopathy. Nat Rev Cardiol 2010; 7(4): 187-193.
238. Tashkin DP, Soares JR, Helper RS, et al. Cannabis, 1977. Ann Intern Med 1978; 89(4): 539-549.
239. Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 1972; 287(5): 209-212.
240. Tashkin DP, Levisman JA, Abbasi AS, et al. Short-term effects of smoked marihuana on left ventricular function in man. Chest 1977; 72(1): 20-26.
241. Liu J, Gao B, Mirshahi F, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000;346(Pt 3): 835-840.
242. Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 2009; 84(3): 378-386.
243. Rajesh M, Mukhopadhyay P, Hasko G, et al. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008; 377(4): 1248-1252.
244. Deusch E, Kress HG, Kraft B, et al. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 2004;99(4):1127-1130, table of contents.
245. Rajesh M, Mukhopadhyay P, Batkai S, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293(4): H2210-2218.
246. Takeda S, Usami N, Yamamoto I, et al. Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab Dispos 2009; 37(8): 1733-1737.
247. Jiang LS, Pu J, Han ZH, et al. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009; 81(4): 805-813.
248. Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol 2010; 105(4): 465-477.
249. Singla S, Sachdeva R, Mehta JL. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol 2012; 35(6): 329-335.
250. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299(13): 1547-1560.
251. O'Leary DH, Reuwer AQ, Nissen SE, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011; 97(14): 1143-1150.
252. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 376(9740): 517-523.
253. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103(23): 2805-2809.
254. Mukamal KJ, Maclure M, et al. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 2008; 155(3): 465-470.
255. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 2007; 118(2): 141-144.
256. Sidney S, Beck JE, Tekawa IS, et al. Marijuana use and mortality. Am J Public Health 1997; 87(4): 585-590.
257. Calabria B, Degenhardt L, Hall W, et al. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010; 29(3): 318-330.
258. Polichetti G, Cocco S, Spinali A, et al. Effects of particulate matter (PM(10), PM(2.5) and PM(1)) on the cardiovascular system. Toxicology 2009; 261(1-2): 1-8.